Page last updated: 2024-11-12

morinidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

morinidazole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11644726
CHEMBL ID3884248
MeSH IDM0543964

Synonyms (22)

Synonym
CS-5058
unii-tupwg40jal
morinidazole
HY-15781
NCGC00485480-01
morponidazole [inn]
morponidazole
(+/-)-1-(2-methyl-5-nitro-1h-imidazol-1-yl)-3-morpholinopropan-2-ol
morinidazole [who-dd]
TUPWG40JAL ,
92478-27-8
CHEMBL3884248
Z1516471620
DB15098
1-(2-methyl-5-nitro-1h-imidazol-1-yl)-3-morpholinopropan-2-ol
F85285
MS-23827
1-(2-methyl-5-nitroimidazol-1-yl)-3-morpholin-4-ylpropan-2-ol
DTXSID201031280
1-(2-methyl-5-nitro-1h-imidazol-1-yl)-3-(morpholin-4-yl)propan-2-ol
EN300-6504759
AKOS040733770

Research Excerpts

Overview

Morinidazole is a new third-generation 5-nitroimidazol antimicrobial drug. It is used for the treatment of amoebiasis, trichomoniasis, and anaerobic bacterial infections.

ExcerptReferenceRelevance
"Morinidazole is a novel 5-nitroimidazole antimicrobial drug that undergoes extensive metabolism in humans via N(+)-glucuronidation (N(+)-glucuronide of S-morinidazole [M8-1] and N(+)-glucuronide of R-morinidazole [M8-2]) and sulfation (sulfate conjugate of morinidazole [M7]). "( Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearance of the conjugated metabolites.
Chen, X; Li, X; Xie, C; Zhang, Y; Zhong, D; Zhong, K, 2014
)
2.09
"Morinidazole is a novel 5-nitroimidazole derivative used for the treatment of amoebiasis, trichomoniasis, and anaerobic bacterial infections. "( A chiral high-performance liquid chromatography-tandem mass spectrometry method for the stereospecific determination of morinidazole in human plasma.
Chen, X; Gao, Z; Li, Q; Zhong, D; Zhong, K, 2014
)
2.05
"Morinidazole is a new third-generation 5-nitroimidazole antimicrobial drug. "( Simultaneous determination of morinidazole, its N-oxide, sulfate, and diastereoisomeric N(+)-glucuronides in human plasma by liquid chromatography-tandem mass spectrometry.
Chen, X; Gao, R; Li, H; Liu, K; Shi, R; Xia, Y; Zhong, D, 2012
)
2.11

Toxicity

ExcerptReferenceRelevance
" Drug-related adverse events occurred less frequently with morinidazole (32."( Efficacy and safety of morinidazole in pelvic inflammatory disease: results of a multicenter, double-blind, randomized trial.
Cao, C; Luo, A; Wang, S; Weng, D; Wu, P; Zheng, H, 2017
)
1.01

Pharmacokinetics

Changes in pharmacokinetic parameters of morinidazole and M4-1 are seen in patients with RI and may be clinically important. This method could be a useful method for clinical pharmacokinetics studies. It was applied to a study involving 11 renal insufficiency patients and 11 healthy volunteers.

ExcerptReferenceRelevance
" This method could be a useful method for clinical pharmacokinetic studies of morinidazole and its carbonylation metabolite, and it has been applied to a pharmacokinetic study involving 11 renal insufficiency patients and 11 healthy volunteers."( Simultaneous determination of morinidazole and its carbonylation metabolite in human plasma: application to a pharmacokinetic study involving renal insufficiency patients and healthy volunteers.
Huang, Y; Huang, Z; Mu, L; Pei, Q; Tan, H; Xie, F; Yang, G; Yu, P; Yuan, H, 2013
)
0.91
" In both groups, maximum plasma concentration of morinidazole was reached within 1 hour, while the tmax of M4-1 differed greatly."( Pharmacokinetics of single-dose morinidazole in patients with severe renal impairment.
Huang, J; Huang, L; Huang, YY; Liu, JS; Pei, Q; Tan, HY; Yang, GP; Yi, B; Yuan, H; Zhang, H, 2014
)
0.94
" Changes in pharmacokinetic parameters of morinidazole and M4-1 are seen in patients with RI and may be clinically important."( Pharmacokinetics of single-dose morinidazole in patients with severe renal impairment.
Huang, J; Huang, L; Huang, YY; Liu, JS; Pei, Q; Tan, HY; Yang, GP; Yi, B; Yuan, H; Zhang, H, 2014
)
0.95
" After 7 days of exposure to 200 mg of ketoconazole once daily, the AUC0-t and Cmax of the parent drug were not affected significantly."( Effects of rifampin and ketoconazole on pharmacokinetics of morinidazole in healthy chinese subjects.
Chen, X; Gao, R; Pang, X; Zhang, Y; Zhong, D; Zhong, K, 2014
)
0.64

Compound-Compound Interactions

ExcerptReferenceRelevance
"To study the drug-drug interaction of morinidazole and warfarin and its application, a sensitive and rapid liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was developed for the determination of R-warfarin/S-warfarin in human plasma."( [Enantioselective determinination of R-warfarin/S-warfarin in human plasma using liquid chromatography-tandem mass spectrometry and its application in a drug-drug interaction study].
Chen, XY; Jin, S; Liu, K; Zhang, YF; Zhong, DF, 2012
)
0.65

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1335738Antiparasitic activity against metronidazole sensitive Trichomonas vaginalis ATCC 33592 after 48 hrs by trypan blue exclusion assay2016European journal of medicinal chemistry, Nov-29, Volume: 1242-Methyl-4/5-nitroimidazole derivatives potentiated against sexually transmitted Trichomonas: Design, synthesis, biology and 3D-QSAR study.
AID1335752Potency index, ratio of metronidazole MIC to compound MIC for metronidazole resistant Trichomonas vaginalis ATCC 501432016European journal of medicinal chemistry, Nov-29, Volume: 1242-Methyl-4/5-nitroimidazole derivatives potentiated against sexually transmitted Trichomonas: Design, synthesis, biology and 3D-QSAR study.
AID1335740Cytotoxicity against human HeLa cells after 24 hrs by MTT assay2016European journal of medicinal chemistry, Nov-29, Volume: 1242-Methyl-4/5-nitroimidazole derivatives potentiated against sexually transmitted Trichomonas: Design, synthesis, biology and 3D-QSAR study.
AID1335739Antiparasitic activity against metronidazole resistant Trichomonas vaginalis ATCC 50143 after 48 hrs by trypan blue exclusion assay2016European journal of medicinal chemistry, Nov-29, Volume: 1242-Methyl-4/5-nitroimidazole derivatives potentiated against sexually transmitted Trichomonas: Design, synthesis, biology and 3D-QSAR study.
AID1335742Selectivity index, ratio of IC50 for human HeLa cells to MIC for metronidazole resistant Trichomonas vaginalis ATCC 501432016European journal of medicinal chemistry, Nov-29, Volume: 1242-Methyl-4/5-nitroimidazole derivatives potentiated against sexually transmitted Trichomonas: Design, synthesis, biology and 3D-QSAR study.
AID1335741Selectivity index, ratio of IC50 for human HeLa cells to MIC for metronidazole sensitive Trichomonas vaginalis ATCC 335922016European journal of medicinal chemistry, Nov-29, Volume: 1242-Methyl-4/5-nitroimidazole derivatives potentiated against sexually transmitted Trichomonas: Design, synthesis, biology and 3D-QSAR study.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's13 (81.25)24.3611
2020's3 (18.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.62 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index6.03 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (25.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]